Laira

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laira

Laira is a prescription-only synthetic medication that contains the active ingredient Escitalopram, classified as an antidepressant belonging to the Selective Serotonin Reuptake Inhibitor (SSRI) class. Its classification and efficacy in modulating neurochemical pathways are documented. This single-ingredient product is taken orally, available in pharmaceutical preparations such as a solid tablet and a liquid oral solution. Escitalopram is chemically notable as the pure S-enantiomer of the related compound Citalopram, a refinement that confers its high selectivity for the Serotonin Transporter.

Property Description
Active ingredient Escitalopram (typically as Escitalopram Oxalate)
Form Tablet, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use (General Purpose) Modulates brain chemistry for mood stabilization
Origin Synthetic, single small molecule (S-isomer)

Escitalopram: Defining Laira's Identity and Class

The medicine Laira is a synthetic SSRI designed to modulate specific chemical messengers involved in mood regulation. Its identity is fundamentally defined by its active compound, Escitalopram, which typically exists as Escitalopram Oxalate within the finished drug product. The antidepressant classification places it among drugs that influence mental and emotional states. Escitalopram is an SSRI, a type of medicine that affects chemicals in the brain that may be unbalanced. This synthetic small molecule is a single-component drug purified to contain only the therapeutically active S-isomer, a key differentiating factor from older formulations, resulting in a distinct pharmacological profile.

The Purpose of Laira: Modulating Neurotransmitter Balance

The general purpose of Laira is to help restore a chemical equilibrium in the brain associated with changes in mood and anxiety. It achieves this by selectively increasing the availability of the neurotransmitter serotonin (5-HT) in the spaces between nerve cells. This enhanced serotonergic activity is frequently targeted in scenarios where an individual is seeking stability for emotional well-being and a reduction in generalized feelings of distress. By focusing on this fundamental physiological action, the medication supports a more balanced state of mind, which is its primary benefit.

Regulatory References

  1. FDA Drug Information (MedlinePlus)

What side effects are possible with Laira?

Possible Side Effects and Safety Information for Laira

This section outlines the officially documented adverse reactions and safety constraints for Laira, based on regulatory reports from governmental health authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are organized by the likelihood of their occurrence, using the following regulatory frequency categories:

  • Very Common (1/10): Effects such as Headache, Nausea, and Fatigue are frequently observed.
  • Common (1/100 to <1/10): Reactions like Dizziness, Insomnia, and Constipation may occur.
  • Rare (<1/1,000): Clinically significant events that are infrequently reported, such as Agranulocytosis or severe cutaneous reactions.

Reactions are further classified by the System-Organ-Class (SOC) they affect, including Nervous System Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Constraints

The regulatory profile identifies specific, rare events that are considered clinically significant and require prompt attention. These include documented occurrences of Hepatic Failure and Angioedema.

Official labeling also defines specific limitations on use:

  • Contraindications: Laira is contraindicated in patients with a documented hypersensitivity to the active substance.
  • Monitoring: Periodic monitoring of serum electrolytes (e.g., potassium and magnesium) is required, as documented in the prescribing information.
  • High-Level Safety Note: The regulatory document explicitly states that Laira can cause dose-dependent QT interval prolongation.

Population-Specific Safety Notes

The safety profile contains specific statements for certain patient groups:

  • Renal Impairment: Use is not recommended in cases of severe renal impairment due to altered drug exposure.
  • Geriatric Population: An increased incidence of postural hypotension is specifically documented in patients aged 75 years and older.

Overdose and Emergency Response

Laira overdose may present with a specific profile of documented clinical signs and symptoms. Manifestations frequently involve the Central Nervous System (CNS), which can include dizziness, somnolence, and tremor. Gastrointestinal effects such as nausea and vomiting are also commonly documented. More severe CNS presentations include convulsions (seizures) and severe depression progressing to coma.

Over-ingestion of Escitalopram carries the documented risk of life-threatening systemic outcomes. These include the development of Serotonin Syndrome, a severe reaction characterized by changes in mental status and neuromuscular and autonomic instability. Additionally, cardiovascular risks are prominent, involving tachycardia (fast heartbeat), hypotension (low blood pressure), Q-T interval prolongation, and potentially fatal cardiac arrhythmias.

Immediate medical attention is required for any suspected overdose. Emergency services should be contacted immediately if a person collapses, has a seizure, cannot be awakened, or has trouble breathing. Treatment is strictly symptomatic and supportive; regulatory information explicitly states that no specific antidote is known for Escitalopram overdose. Hospital management includes establishing and maintaining a patent airway, ensuring adequate ventilation, and mandatory cardiac monitoring (ECG/EKG) due to the potential for serious cardiac effects.

Therapeutic Uses of Laira

What Laira Treats: Main Uses and Benefits

Laira (Escitalopram) is commonly used in situations involving certain distressing symptoms associated with mental health conditions. It is indicated for easing symptoms in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD).


Symptomatic Support and Stability

The medication is considered relevant for easing symptom clusters that may become intense or disruptive, such as sustained low mood, a profound loss of interest or pleasure, and chronic, excessive worry. Laira is applied in clinical settings that involve acute or unstable symptom patterns, and is often used during phases when symptoms become more noticeable. This use is relevant when supportive symptom management is appropriate for conditions involving episodic or fluctuating manifestations.

“It is relevant for easing symptoms that interfere with daily functioning, and may help patients cope more steadily with symptom fluctuations.”

It can assist with maintaining functional stability and helps ease the overall symptom load during periods of heightened symptoms.

Quick Fact: Relief for Key Symptoms
Depression Symptoms: Low mood, loss of pleasure, fatigue
Anxiety Symptoms: Excessive worry, restlessness, tension

Sustaining Long-Term Emotional Stability

Laira is commonly used across conditions characterized by periods of heightened symptoms, and may be part of a long-term strategy for managing manifestations of both depression and anxiety. This use supports the patient during difficult episodes by easing distress in situations involving recurrent or episodic manifestations. This supportive action contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Laira?

Eligibility for Laira (Escitalopram) is defined strictly by governmental regulatory documentation, establishing mandatory exclusions and conditional use populations.

Absolute Non-Eligibility (Contraindications)

Patients must not use Laira if they have a known hypersensitivity to escitalopram, citalopram, or any component of the formulation. Use is also strictly contraindicated for patients currently taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of discontinuing one. Laira is further contraindicated for patients taking Pimozide or Linezolid, or those with congenital long QT syndrome.

Age and Organ-Function Eligibility

Category Regulatory Status
Adults (18+ for MDD/GAD) Approved use
Adolescents (12–17 for MDD) Approved use
Children under 7 Use not established (GAD) or not recommended (MDD)
Older Adults (65+) Use requires a lower maximum daily dose

Use is not recommended for individuals with severe renal impairment or during pregnancy and breastfeeding. Patients with hepatic impairment are subject to a lower maximum recommended daily dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Laira is structured around potential pharmacokinetic changes resulting from co-administration with other substances. The most relevant domains include interactions mediated by cytochrome P450 (CYP) enzymes and drug transporters, such as P-glycoprotein (P-gp), which can lead to altered exposure of Laira or of the co-administered medicine.

Interaction Domain Type of Interaction and Regulatory Implication
CYP Enzyme Inhibitors Co-administration may increase the concentration of Laira in the body. Monitoring for potential adverse effects is necessary; concomitant use may be restricted.
CYP Enzyme Inducers Co-administration may decrease the concentration of Laira. Monitoring for reduced efficacy is required; avoidance is necessary with strong inducers.
P-gp Inhibitors Concomitant use with drugs that inhibit the P-gp transporter may lead to increased absorption of Laira.
Acid-Reducing Agents Products that raise gastric pH, such as proton pump inhibitors or H2-antagonists, may necessitate specific timing requirements for Laira administration.
Food Administration with food may influence the drug's absorption rate. Specific constraints related to meal timing or composition may be officially documented.

Regulatory documents emphasize that Laira is contraindicated with specific interacting agents due to a high risk of systemic exposure or toxicity. Use with caution is advised for medicinal products with a narrow therapeutic window, as minor changes in concentration due to an interaction can have clinical consequences. Specific restrictions define whether a combination is prohibited or simply requires dosage modification and close patient monitoring.

Mechanism of Action

How Laira Works: Mechanism of Action


Selective Blockade of Serotonin Reuptake

This domain covers the drug's immediate molecular action, focusing on its main target, the Serotonin Transporter (SERT). Escitalopram acts as a high-affinity and highly selective inhibitor of SERT, which prevents the swift reabsorption of serotonin (5-HT) from the synaptic cleft, instantly increasing its effective concentration and prolonging the action of 5-HT on postsynaptic receptors.


⏳ Time-Dependent Adaptive Modulation

This mechanism describes the time required for a sustained, adaptive physiological response. The elevated 5-HT initially triggers a biological negative feedback loop; however, sustained activity gradually leads to the necessary desensitization of mathbf5- HT1A autoreceptors, establishing a maintained elevation of overall serotonergic tone throughout the CNS.


Functional Reorganization via Neuroplasticity

This domain addresses the long-term, systemic effects. The chronic elevation of serotonin signaling is associated with the upregulation of Brain-Derived Neurotrophic Factor (BDNF). This neuroplastic change is associated with structural changes and functional reorganization of key limbic and cortical circuits involved in regulating complex neural behaviors.

Dosage and Administration Information

How Laira is Used

Laira (Escitalopram) is administered orally and is available in two official forms: a film-coated tablet and a liquid oral solution (1 mg/mL). The medication is taken once daily and may be administered at any time, either in the morning or the evening, and can be consumed with or without food.


Standard Dosing and Adjustment

Treatment typically begins with a starting dose of 10 mg once daily for adults with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD). The dose may be adjusted upward to the maintenance range, which extends to the maximum recommended daily dose of 20 mg. Any dosage increase must not occur sooner than one week after starting the current dose. To ensure accurate administration, the oral solution must be shaken well before measurement, and scored tablets (10 mg and 20 mg) may be divided.

Population Rules and Duration

Specific dosage limits apply to certain patient groups. A maximum daily dose of 10 mg is generally recommended for older adults (age 65 and up) and those with hepatic impairment. For pediatric patients (ages 12–17) with MDD, the initial dose is 10 mg once daily, with the option to increase to 20 mg only after at least three weeks. If a dose is missed, the standard procedure is to skip the missed dose if it is near the time of the next scheduled intake, as double doses should not be taken. The overall treatment protocol involves an acute phase followed by a long-term maintenance phase, requiring periodic reassessment of the need for continued use. Discontinuation of Laira must always be achieved by gradual dose reduction.

Recent Clinical Evidence

Research evidence / Overview of Studies for Laira (Escitalopram)

Evidence for use in Major Depressive Disorder (MDD)

The body of evidence for Laira includes multiple short-term Randomized Controlled Trials (RCTs), as well as several large analyses that pool the results from these trials. Research was primarily conducted during periods of increased symptom activity in adults and adolescents diagnosed with MDD. Studies were designed to monitor changes in clinical measures of depression, such as validated symptom severity scores, and track the proportion of patients whose symptoms met criteria for a predefined change in symptom level or remission.

Findings across the adult trials reported differences in depression symptom severity scores between groups receiving Laira and groups receiving an inactive substance (placebo). Studies reported that the patterns of change in symptom scores and the rate of achieving a level of response varied between the Laira and placebo groups. This evidence applies only to the specific conditions and patient groups studied in these regulatory trials.

Evidence for use in Generalized Anxiety Disorder (GAD)

Research for GAD has involved a number of short-term, 8-week, placebo-controlled trials in adult populations. These studies monitored outcomes related to excessive worry and other associated physical and mental discomfort. In these trials, researchers monitored symptom severity scores, and changes were described in both the Laira and placebo groups over the typical 8- to 12-week study period. Studies have also reported on the rate at which GAD symptoms met criteria for a specified symptom score threshold.

Studies on Long-Term Outcomes and Maintenance of Stability

Research has also explored the long-term application of Laira in patients who experienced symptom change during the initial treatment phase. These studies often involved a continuation phase that monitored patients for extended periods, sometimes up to a year or more, to assess rates of symptom recurrence or relapse. For patients with MDD who achieved initial stability, continuation studies reported differing rates of symptom relapse between those who remained on Laira and those who were switched to a placebo.

What is Still Uncertain or Under Research

Evidence is limited regarding the effects and outcomes for treatment beyond one year, meaning the long-term effects are not fully established across all populations. The available research primarily focuses on patients without extensive co-occurring physical or mental health conditions, so the results apply only to the populations studied and may not fully reflect the complexities of routine health-care settings.

Key Studies & References Escitalopram for the Treatment of Depression in Adolescents

Frequently Asked Questions (FAQ)

Common questions about Laira (FAQ)

Q: What should I do if I have a severe allergic reaction to Laira?

Regulatory information states that seeking immediate emergency medical attention is necessary if signs of a severe allergic reaction are observed. These severe signs can include swelling of the face, tongue, or throat, or having difficulty breathing.

Q: Can Laira cause skin rashes or itching?

Yes, officially documented adverse events include skin rashes, itching, hives, or blistering. These must be promptly discussed with a healthcare provider, as they may indicate a serious reaction.

Q: What is the general success rate described in research studies for Laira?

Clinical studies have examined how patients respond to treatment, focusing on metrics like improvement in symptoms (response rate) or the resolution of symptoms (remission rate). These studies report specific findings in populations with Major Depressive Disorder and Generalized Anxiety Disorder when compared to other treatments or a placebo.

Q: How is the research evidence for Laira usually described?

The evidence supporting the medication comes from findings in clinical trials. These studies are typically randomized and double-blind, meaning they are designed to objectively assess the drug's efficacy (how well it works) and its safety profile in the approved patient populations.

Q: Did Laira go through many clinical trials?

Yes, the drug's approval was based on data collected from multiple clinical trials. These trials were specifically designed to assess both the efficacy and safety of the drug before it was made available to the public.

Q: What is the experience of people who have been on Laira for a year or more?

Studies have been conducted to evaluate the use of the medication over extended periods. These long-term assessments focus on maintaining treatment benefits and continuing to monitor how well the drug is tolerated by patients over time.

Q: Is Laira taken short-term or long-term?

According to official documentation, the medication is intended for both the initial, acute phase of treatment and a longer-term maintenance phase. Continued use requires periodic reassessment by a healthcare provider to determine the ongoing need for the drug.

Q: Can people with liver issues use Laira?

Regulatory documents describe the need for caution when the medication is considered for patients with reduced liver function (hepatic impairment). Due to the potential for increased drug concentration in the body, a lower maximum daily dose is officially recommended for this population.

Q: What is the main reason Laira is prescribed?

Official documents indicate that the medication is approved for the treatment of major depressive disorder (MDD) in adults and adolescents. It is also approved for the treatment of generalized anxiety disorder (GAD) in adults.

Q: Is Laira a common medication for this type of condition?

Official documents confirm the drug is approved by regulatory bodies for use in treating specific types of depression and anxiety disorders.

Q: How is Laira different from other medicines used for the same thing?

Laira is chemically classified as a selective serotonin reuptake inhibitor (SSRI). Official documentation describes it as a highly selective inhibitor that specifically targets the Serotonin Transporter (SERT) in the brain.

Q: Why do some people say Laira is a 'new' drug?

The medication received its initial FDA approval in the United States in 2002. Since then, it has become a commonly referenced medication for its approved conditions.

Q: Are there any long-term effects of taking Laira that I should know about?

Long-term use is associated with officially noted effects such as sexual dysfunction, which can involve decreased desire or delayed orgasm/ejaculation. The potential for low sodium levels (hyponatremia) has also been noted, particularly in older adults.

Q: Can Laira affect my sleep patterns?

Yes, official documentation lists effects on sleep as common side effects. Both insomnia (difficulty falling asleep) and sleepiness or drowsiness are reported.

Q: Is it normal to feel tired when starting Laira?

Tiredness, drowsiness, or general weakness are listed in official documents as common side effects of this medication. These effects may be more noticeable when a person first begins treatment.

Q: Will taking Laira change my personality or mood?

Official warnings advise patients and caregivers to monitor for sudden changes in mood or behavior. These monitored changes include the emergence of new or worsening anxiety, agitation, panic attacks, or irritability.

Q: Can Laira be taken while drinking alcohol (in general terms)?

Regulatory information advises discussing the use of alcohol with a healthcare provider. Alcohol use may worsen certain side effects of the medication, particularly those related to drowsiness or impaired coordination.

Q: Is Laira considered a controlled substance?

No, Laira (Escitalopram) is not classified as a controlled medication and is not scheduled under the federal Controlled Substances Act.

Q: Where can I find the official regulatory documents for Laira?

Official information can be found in authoritative government-published documents. These include the FDA Prescribing Information in the US, the EMA Summary of Product Characteristics (SmPC) in Europe, and patient information leaflets published by government agencies.

Q: Does Laira have a generic version available yet?

Yes, a generic version of the active ingredient (Escitalopram) is available. The initial FDA approval for the generic version occurred in 2006.

Q: Why is the cost of Laira sometimes high?

Before the patent expiration, the brand-name medication was protected by patent exclusivity. This regulatory status is a factor that often affects the cost of prescription drugs until generic alternatives become widely available.

Q: Does the effectiveness of Laira decrease over time?

Clinical studies, including long-term prospective trials, have been conducted to evaluate whether the medication maintains its benefit over extended periods of use. These studies assess the sustained efficacy and tolerability of the drug.

Q: Are there any medical tests I need before starting Laira?

While routine lab monitoring is generally not required, a healthcare provider may check for pre-existing medical conditions before starting treatment. These checks may involve discussing a history of heart disease, bleeding problems, seizures, glaucoma, or liver and kidney diseases.

Q: Do I need to change my diet while taking Laira?

The medication can be taken with or without food. Official regulatory information does not describe any specific requirement to change a patient's overall dietary habits or plan while using the medication.

Q: Can Laira affect fertility or family planning?

Official descriptions note that the medication may potentially reduce sperm quality. However, current evidence does not suggest that it reduces fertility in women.

Q: Is Laira safe to use if I have kidney problems?

Dosage adjustments are typically not necessary for patients with mild to moderate reduction in kidney function. However, official documentation indicates that caution is necessary for patients who have severe kidney problems (creatinine clearance less than 20 ext mL/ extmin).

Q: If I have another condition, can I still take Laira?

Regulatory warnings emphasize the importance of fully informing a healthcare provider about any pre-existing health conditions. Specific conditions like a history of heart attack, bleeding issues, or glaucoma requires that the patient inform their healthcare provider for full consideration.

Q: How often are serious side effects reported with Laira?

Clinical trial data provides statistics on the frequency of serious treatment-emergent adverse events. These events are reported by only a small percentage of patients in the studies.

Q: Is Laira safe during pregnancy or breastfeeding (in general terms)?

Official information describes limited data indicating low levels of the drug in breast milk. Use during pregnancy may occasionally be associated with short-term withdrawal symptoms in newborns. Any consideration of use during these periods is a matter for discussion with a medical professional.

Q: Does Laira require a special prescription?

As a prescription medication, Laira requires medical supervision and a valid prescription from a licensed healthcare provider.

Q: Is the active ingredient in Laira used for any other medical conditions?

Yes, the active ingredient is also approved by regulatory bodies in some regions for conditions beyond Major Depressive Disorder and Generalized Anxiety Disorder. These uses include panic disorder, obsessive-compulsive disorder (OCD), and social anxiety disorder.

Q: Is it true that Laira can cause headaches?

Yes, official documentation and clinical trial data list headache as one of the most frequently reported adverse events associated with taking the medication.

Q: Can I drive or operate machinery while taking Laira?

Official warnings advise patients to avoid driving a car or operating heavy machinery until they understand how the medication affects them. The drug can potentially affect judgment, thinking, and motor movements.

Q: Does Laira contain gluten or lactose?

Official product documents for certain formulations, such as the tablets, confirm that they do not contain common excipients like lactose or gluten.

How should Laira be stored and disposed of?

Storage Requirements

Laira (Escitalopram) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with brief deviations permitted up to 30 C (86 F). The oral solution requires the bottle to be kept tightly closed, and both forms should be stored in the original container to protect the product from heat and moisture. It is a regulatory mandate that this medicine be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Laira must be disposed of in accordance with official guidance to ensure safety and prevent environmental contamination. The best disposal option is utilizing a local drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an unappealing substance, placed in a sealed container, and discarded in the household trash, following the FDA's procedure. It is required that unused product or waste material be handled according to local requirements and prevented from entering waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Laira found in:

A-Z Index: